Dr. Bishayee is the Director of Research and Professor of Pharmacology at the Lake Erie College of Osteopathic Medicine (Bradenton, Florida). Dr. Bishayee has more than 25 years combined experience in pharmaceutical and biomedical education, research, teaching, and administration. He received his Bachelor of Pharmacy (B.Pharm.), Master of Pharmacy (M.Pharm.), and Ph.D. (cancer prevention) from Jadavpur University, Kolkata, India. Dr. Bishayee performed post-doctoral research at Rutgers University, Newark, New Jersey (formerly University of Medicine and Dentistry of New Jersey) and completed a fellowship in Academic Medicine from Northeast Ohio Medical University (NEOMED, Rootstown, Ohio). Dr. Bishayee’s primary research interest during last two decades encompasses natural products and dietary agents in health and disease. His laboratory is involved in investigating cancer preventive and therapeutic effects of medicinal plants, natural products, dietary and synthetic agents using various pre-clinical models of cancer and underlying mechanisms of action. The various projects of Dr. Bishayee are funded by the National Institutes of Health as well as private pharmaceutical and biotechnological companies. Dr Bishayee has been awarded a United States patent on development of a potential drug for breast cancer prevention and treatment. Dr. Bishayee has published more than 300 peer-reviewed original research papers and authoritative review articles, mostly in high-impact journals, including Nature Reviews Drug Discovery [impact factor (IF) 120.1], Biotechnology Advances (IF 16.0), Trends in Food Science and Technology (IF 15.3), Seminars in Cancer Biology (IF 14.5), Acta Pharmaceutica Sinica B (IF 14.5), Pharmacology and Therapeutics (IF 13.5), Medicinal Research Reviews (IF 13.3), Cancer Treatment Reviews (IF 11.8), Critical Reviews in Food Science and Nutrition (IF 10.2), Biochimica et Biophysica Acta - Reviews on Cancer (IF 11.2), Clinical and Translational Medicine (IF 10.6), Cancer Letters (IF 9.7), Advances in Nutrition (IF 9.3), Cancer and Metastasis Reviews (IF 9.3), and Pharmacological Research (IF 9.3); 22 book chapters; and around 90 conference abstracts, and delivered more than 30 invited presentations at various national and international scientific meetings. Dr. Bishayee is an editorial board member of various reputed journals, such as Pharmacological Research, Phytomedicine (Elsevier), Frontiers in Oncology (Frontiers Media S.A.), Frontiers in Pharmacology, Cancers (MDPI), BMC Complementary and Alternative Medicine (Springer Nature), Current Molecular Pharmacology (Bentham Science), and Anti-Cancer Drugs (Wolters Kluwer) and reviewer of more than 80 reputed journals. Dr. Bishayee edited an Elsevier book “Epigenetics of Cancer Prevention” and guest edited several special issues on natural products and cancer published by leading publishers, such as Elsevier, Springer Nature, MDPI, and Bentham. Dr. Bishayee is a “Highly Cited Researcher” in 2022 and his papers rank in the top 1% by citations for a field or fields (Clarivate, Web of Science). His Scopus h-index is 75 and scholars from all over the world have cited Dr. Bishayee’s published work more than 25,000 times.

Jingwei Xie received his B.S. (1999) and M.S. (2002) from Nanjing University of Technology, China, and his Ph.D. from the National University of Singapore (2007). He worked as a postdoctoral fellow in the Xia group at Washington University in St. Louis (2007‐2010). He is currently a Professor in the Department of Surgery-Transplant and Holland Regenerative Medicine Program at the University of Nebraska Medical Center (UNMC). He has won several prestigious awards including Most Promising New Invention Award at UNMC (2017), Maurer Scientific Achievement Award (2019), CAB Mid-Career Investigator Award (2020), and Distinguished Scientist Award at UNMC (2021). He was recently selected as 2024 AIMBE Fellow. His research interests include biomaterials, drug delivery, wound healing, hemostasis, and regenerative medicine.